Although the incidence of
Lyme disease is highest in children, there are few prospective data on the clinical manifestations and outcomes in children.
We conducted a prospective, longitudinal, community-based cohort study of children with newly diagnosed
Lyme disease in an area of Connecticut in which the
disease is highly endemic. We obtained clinical and demographic information and performed serial antibody tests and follow-up evaluations.
Over a period of 20 months, 201 consecutive patients were enrolled; their median age was 7 years (range, 1 to 21). The initial clinical manifestations of
Lyme disease were a single erythema migrans lesion in 66 percent, multiple erythema migrans lesions in 23 percent, arthritis in 6 percent, facial-nerve palsy in 3 percent, aseptic meningitis in 2 percent, and carditis in 0.5 percent. At presentation, 37 percent of the patients with a single erythema migrans lesion and 89 percent of those with multiple erythema migrans lesions had antibodies against Borrelia burgdorferi. All but 3 of the 201 patients were treated for two to four weeks with conventional antimicrobial therapy, which was administered orally in 96 percent. All had prompt clinical responses. After four weeks, 94 percent were completely asymptomatic (including the two patients whose parents had refused to allow antimicrobial treatment). At follow-up a mean of 25.4 months later, none of the patients had evidence of either chronic or recurrent
Lyme disease. Six patients subsequently had a new episode of erythema migrans.
About 90 percent of children with
Lyme disease present with erythema migrans, which is an early stage of the
disease. The prognosis is excellent for those with early
Lyme disease who are treated promptly with conventional courses of antimicrobial agents.